Vena Vitals vs Andson Biotech
Side-by-side comparison of AI visibility scores, market position, and capabilities
Wearable blood pressure monitoring sticker with OR-grade accuracy; awaiting FDA clearance after 500+ patient clinical studies for hospital surgery and home cardiovascular monitoring.
About
Vena Vitals is a medical device company developing wearable continuous blood pressure monitoring technology — manufacturing adhesive sensor stickers that provide operating room-grade blood pressure accuracy using photoplethysmography (PPG) and proprietary algorithms, without the discomfort or interruption of traditional cuff-based blood pressure measurement. Founded in 2019 in Irvine, California, Vena Vitals has completed clinical studies on 500+ patients and is preparing its FDA submission for clearance to market the device for in-hospital (surgical and critical care) and home monitoring applications.\n\nVena Vitals' wearable patch applies to the wrist or finger and continuously monitors blood pressure beat-by-beat using optical sensors — providing the continuous monitoring currently limited to invasive arterial line catheters in ICUs or intermittent readings from arm cuffs. Continuous non-invasive blood pressure monitoring is clinically valuable during surgery (where blood pressure fluctuates significantly) and for patients with cardiovascular conditions or sleep disorders where blood pressure patterns during sleep and activity provide diagnostic insight. The device targets a significant cost reduction compared to invasive arterial line monitoring.\n\nIn 2025, Vena Vitals is in the regulatory submission phase, positioning for FDA clearance that would unlock commercial deployment in hospitals and the growing consumer remote patient monitoring market. The continuous non-invasive blood pressure market is competitive — Samsung (Galaxy Watch blood pressure), Apple (researching blood pressure for Apple Watch), Withings, and medical device companies including Omron and iHealth are pursuing cuffless blood pressure monitoring. However, most consumer wearable approaches have not achieved clinical-grade accuracy, which is Vena Vitals' key differentiator. FDA clearance would position Vena Vitals for partnerships with hospital systems and RPM (remote patient monitoring) program operators.
Mass spectrometry sample prep and data science platform delivering 100x productivity for biopharma protein analysis; $9.1M from Merck Digital Sciences Studio, NIH, and YC at $1.8M revenue.
About
Andson Biotech is an Atlanta-based healthcare technology company providing mass spectrometry solutions for biopharma and biomanufacturing — offering the DynaCHIP hardware system (a novel mass spectrometry sample preparation platform) and DynaMARK data science module that together deliver up to 100x productivity improvements in protein and biomolecule analysis workflows compared to conventional mass spectrometry setups. Backed by Y Combinator, Merck Digital Sciences Studio, and NIH with $9.1 million raised, Andson achieved $1.8 million in revenue as of December 2024.
AI Visibility Head-to-Head
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.